Companies /Healthcare

Dyne Therapeutics Inc

NASDAQ: DYN Biotechnology
$17.16
▲ $0.15 (+0.88%) today
Markets closed · 11:43pm ET

DYN at a Glance

Valuation
Market cap
$3.2B
Profitability
EPS (TTM)
$-3.62
Price
52-week range
$14 – $27
Street target
$34.33

Headquartered in Waltham, MA Fiscal year ends December NASDAQ: DYN dyne-tx.com

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases. Its drugs are designed to target muscle and the central nervous system and address the root cause of disease. They are built on the company's FORCE platform.

The lead program, zeleciment rostudirsen (z-rostudirsen, DYNE-251), treats Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. Its Biologics License Application is under FDA priority review, with a PDUFA target action date of January 21, 2027. The confirmatory Phase 3 FORZETTO trial is ongoing.

The second clinical program, zeleciment basivarsen (z-basivarsen, DYNE-101), treats myotonic dystrophy type 1 (DM1). It is being studied in the Phase 1/2 ACHIEVE trial and the confirmatory Phase 3 HARMONIA trial.

Preclinical programs include four DMD candidates targeting exons 44, 45, 53 and 55 (DYNE-244, DYNE-245, DYNE-253, DYNE-255), plus programs in facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease.

The company has no product revenue. It funds operations from cash, cash equivalents and marketable securities and is building commercial capabilities ahead of a potential first launch. Updated

Latest Activity

DYNDyne Therapeutics
Q3 2026
EPS
-$1.06
est -$0.88-20.2%
Revenue
$0K

The loss widened, missing expectations, because Dyne is spending ahead of a launch it doesn't have yet: G&A more than doubled to $35.3 million on headcount for z-rostudirsen, whose FDA decision lands January 21, 2027. Cash of $1.13 billion funds operations into the second quarter of 2028, making the approval the whole story.

Quarterly EPS — reported vs estimate

DYN Coverage

Frequently Asked Questions

What does Dyne Therapeutics do?

Dyne Therapeutics is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases. Its drugs are designed to target muscle and the central nervous system and address the root cause of disease.

What is the DYN stock price target?

The Wall Street consensus 12-month price target for DYN is $34.33.